Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 07, 2016 08:30 ET | Source: Mateon Therapeutics

Mateon Therapeutics to Present at the 18th Annual Rodman and Renshaw Global Investment Conference in New York on September 12, 2016

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a clinical-stage biopharmaceutical company developing vascular disrupting agents for the...
August 03, 2016 08:00 ET | Source: Mateon Therapeutics

Mateon Provides Corporate Update and Reports Second Quarter 2016 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment...
July 21, 2016 08:00 ET | Source: Mateon Therapeutics

Mateon Announces Enrollment of First Patient in Phase 2 Portion of PAZOFOS Study in Recurrent Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., July 21, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment...
June 23, 2016 08:00 ET | Source: Mateon Therapeutics

Mateon Announces Initiation of FOCUS Study in Platinum-Resistant Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., June 23, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment...
June 20, 2016 11:00 ET | Source: Mateon Therapeutics

UPDATE -- Mateon Therapeutics to Present New Improved Survival Outcomes for CA4P in Recurrent Ovarian Cancer at June 27 Investor Event

Updated data shows improvement in overall survival of 3.2 months for all CA4P-treated patients Improvement in overall survival is 5.6 months for CA4P-treated patients with measurable disease SOUTH...
June 20, 2016 07:15 ET | Source: Mateon Therapeutics

Mateon Therapeutics to Present New Improved Survival Outcomes for CA4P in Recurrent Ovarian Cancer at June 27 Investor Event

Updated data shows improvement in overall survival of 3.2 months for all CA4P-treated patients Improvement in overall survival is 5.6 months for CA4P-treated patients with measurable disease SOUTH...
June 17, 2016 10:15 ET | Source: Mateon Therapeutics

OXiGENE Announces Name Change to Mateon Therapeutics

SOUTH SAN FRANCISCO, Calif., June 17, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for orphan oncology...
June 10, 2016 08:30 ET | Source: OXiGENE, Inc.

OXiGENE Receives U.S. Orphan Drug Designation for CA4P to Treat Glioma

SOUTH SAN FRANCISCO, Calif., June 10, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan...
May 24, 2016 06:30 ET | Source: Mateon Therapeutics

OXiGENE Announces Results of Phase 2 Study of CA4P in Recurrent Ovarian Cancer Published in Journal of Clinical Oncology

Study met primary endpoint of improvement in progression free survival Preliminary data show improvement in overall survival of 2.6 months SOUTH SAN FRANCISCO, Calif., May 24, 2016 (GLOBE...
May 09, 2016 08:00 ET | Source: Mateon Therapeutics

OXiGENE Reports First Quarter 2016 Financial Results

SOUTH SAN FRANCISCO, Calif., May 09, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right